Stabenow, other state leaders to sound alarm against the competitive procurement process for prepaid inpatient health plansLANSING, Mich., Sept. 04,…
Phase 2 ACUITY trial results for Privosegtor (OCS-05) in acute optic neuritis to be presented in EURETINA late-breaking session Expanded…
ZUG, Switzerland, Sept. 01, 2025 (GLOBE NEWSWIRE) -- Phase 2 ACUITY trial results for Privosegtor (OCS-05) in acute optic neuritis…
Illustrative image Laboratory, Boehringer Ingelheim This press release is not intended for UK and US media. HERNEXEOS® (zongertinib tablets) has been…
Compared with tirzepatide, Wegovy® (semaglutide 2.4 mg) showed a significant 57% greater reduction in the risk of heart attack, stroke…
OAKLAND PARK, FL / ACCESS Newswire / August 24, 2025 / EndoUVTech, a medical device innovator pioneering UV laser technology…
WALTHAM, Mass. and DUBLIN and EMERYVILLE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage…
WALTHAM, Mass., DUBLIN, Ireland and EMERYVILLE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage…
Combining intelligent tools and personalized support, RethinkCare empowers employers, families and caregivers with clinically validated resources, expert coaching and navigation…
ENX-CL-05-001 Trial: 3-months topline data - In the overall modified intention-to-treat (mITT) population, improvements across all efficacy and secondary endpoints, including…